|Product Name:||Levomefolate Calcium||CAS No:||151533-22-1|
|Purity:||98% Min||Shelf Life:||2 Years|
|Application:||Pharmaceutical API||Storage:||Cool And Dry Place|
|Package:||1KG Per Bag|
API Powder CAS 151533-22-1
API Powder L-Methylfolate Calcium CAS 151533-22-1 Nootropic L-5-Mthf-Ca and Levomefolate Calcium
About this product
Calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) is a synthetic derivative of folic acid, the predominant, naturally occurring form of folate. L-5-methyltetrahydrofolate, also known as levomefolic acid, is the primary biologically active form of folate. It is involved in many important in vivo process including DNAreproduction, the cysteine cycle and the regulation of homocysteine. It is also the form found in circulation and transported across membranes into tissues and across the blood-brain barrier. It can be used for the treatment of major depressive disorder, cardiovascular disease and cancer. It can be used for the treatment of hyperhomocysteinemia regularly found in hemodialysis patients.
Mainly for folic acid antagonists (such as methotrexate, pyrimethamine, benzyl cefalexin and trimethoprim) antidote, it's usually used for prevention of methotrexate dose or overdose treatment caused severe toxic effects.
Folic acid treatment of the following diseases, such as inflammatory diarrhea and protein-energy malnutrition (poor nutrition), pregnancy or infancy megaloblastic anemia caused by poor.
As adjuvant therapy for colon cancer, rectal cancer.
Combined with 5-FU and treatment of digestive tract tumors or other 5-FU-sensitive tumors. High-dose CF used in conjunction with 5-FU (LF), the basic programme is currently the treatment of colon and rectal cancer.
For children with leukemia, lymphoma, and osteosarcoma, such as high dose MTX treatment when rescued.
|Product Name||CAS No.||Product Name||CAS No.|
All products are exported for Lab & Research use in legal and Non-patented area only. Products may not be used in human or animals. Individuals are fully responsible for all consequences arising therefrom.
Contact Person: kate